Hunan Vigor Appears at the 23rd CPHI World Pharmaceutical Exhibition, with three core products: Artemisinin, Hesperidin and Diosmin
Hunan Vigor Appears at the 23rd CPHI World Pharmaceutical Exhibition, Demonstrating Core Competitiveness
From June 24th to 26th, the 23rd CPHI China (CPHI China 2025), known as the "vane of the pharmaceutical industry", came to a successful conclusion at the Shanghai New International Expo Center. This year's exhibition reached a new record in scale, with a 230,000 - square - meter exhibition space gathering more than 3,500 top enterprises from 62 countries and regions. Among the over 100,000 professional visitors, there were 23,000 international purchasers. It has jointly built a communication platform covering the entire industry chain of APIs, excipients, preparations, packaging, etc., and has become a core hub for the global pharmaceutical industry to gain insight into trends and negotiate cooperation.
Hunan Vigor participated in the exhibition with three core products: artemisinin, hesperidin and diosmin. The exhibition attracted the attention of purchasers from the European Union, Southeast Asia, South America and other regions. During the three days,we received many professional visitors with clear cooperation intentions, showing our own characteristics in the plant extraction exhibition area.
As an important global supplier of artemisinin, the company has a stable annual production capacity of 120 tons, accounting for 25% of the global supply. Artemisinin, as the core starting material for anti - malaria drugs, is an indispensable key substance in the global malaria prevention and control system. Although it cannot be independently certified by public markets such as WHO or the Global Fund as a raw material, through joint evaluation with Indian API manufacturers and pharmaceutical enterprises, it has finally been successfully included in the public procurement system. This has built an important bridge for the raw material guarantee of the global anti - malaria cause, enabling this key substance to serve the global malaria prevention and control work more efficiently.
The hesperidin and diosmin products launched by the company have also attracted much attention. As important achievements of the company's diversified development strategy, the put into production of hesperidin and diosmin production lines has further enriched the company's product portfolio. Among them, diosmin, as a high - value - added product extracted from hesperidin, has a broad market prospect. Through continuous technological research and development and process optimization,Hunan vigor has successfully realized the large - scale production of hesperidin and diosmin.
This participation not only provided Hunan Vigor with an international stage to show its strength, but also created good opportunities for the company to further expand the global market and strengthen international cooperation. During the exhibition, the company reached preliminary cooperation intentions with a number of international pharmaceutical enterprises, laying a solid foundation for future business expansion.
Looking forward to the future, Hunan Vigor will continue to adhere to the development concept of "technological innovation,adhere to quality", increase investment in research and development and production fields, continuously improve product quality and service level, provide more high - quality products and solutions for the global pharmaceutical market, and contribute to the development of human health undertakings.